Literature DB >> 16462290

Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors.

Louis Alexander1, Lisa Cuchura, B Joyce Simpson, Warren A Andiman.   

Abstract

BACKGROUND: There are limited data concerning determinants of varying clinical progression rates in human immunodeficiency virus type 1 (HIV-1)-infected children. Therefore, we sought to determine whether viral or host factors associated with nonprogressive HIV-1 infection in adults play a role in limiting progression of infection in 5 vertically infected youths, ages 12-18 years, who have displayed no signs of advanced HIV-1 disease or acquired immunodeficiency syndrome despite having received minimal treatment with antiretroviral drugs.
RESULTS: The 5 individuals, whom we characterize as long term survivors, have maintained low loads of HIV-1 RNA in plasma when compared to many of their peers, and have also maintained normal and stable CD4 T-lymphocyte numbers and percentages throughout their lives. Determination of their predominant HIV-1 sequences revealed that 4 of 5 patients harbor virus with markers of resistance to their therapy (one was never treated). Furthermore 2 harbored viral isolates that contained insertions in Gag or Vif that inhibit HIV-1 replication. Moreover, 2 were found to be heterozygous for the CCR2 polymorphism 64I, a genotype associated with slower progression to acquired immunodeficiency syndrome in adults. All 5 expressed the histocompatibility leukocyte antigen DQ1 and 2 had unusual DR/DQ1 phenotypes.
CONCLUSIONS: We believe that the limited antiretroviral therapy received by the long term survivors cannot solely account for their benign clinical status. Therefore, we conclude that other factors, including gene polymorphisms that affect viral replicative capacity, account for the long term survival in some, and deduce that, as in adults, no single factor (virologic or host) can account for this clinical phenotype in all cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462290     DOI: 10.1097/01.inf.0000199299.00345.83

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  A novel single cDNA amplicon pyrosequencing method for high-throughput, cost-effective sequence-based HLA class I genotyping.

Authors:  Simon M Lank; Roger W Wiseman; Dawn M Dudley; David H O'Connor
Journal:  Hum Immunol       Date:  2010-07-30       Impact factor: 2.850

2.  Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.

Authors:  Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Kenneth Tapia; Evelyn Ngugi; Helen Moraa; Elizabeth Maleche-Obimbo; Vincent Otieno; Irene Inwani; Barbra A Richardson; Bhavna Chohan; Julie Overbaugh; Grace C John-Stewart
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

3.  Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.

Authors:  Adriana Weinberg; Ruth Dickover; Paula Britto; Chengcheng Hu; Julie Patterson-Bartlett; Joyce Kraimer; Howard Gutzman; William T Shearer; Mobeen Rathore; Ross McKinney
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

4.  Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.

Authors:  Nívea D Amoêdo; Adriana O Afonso; Sílvia M Cunha; Ricardo H Oliveira; Elizabeth S Machado; Marcelo A Soares
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

5.  Comparison of HIV-1 nef and gag Variations and Host HLA Characteristics as Determinants of Disease Progression among HIV-1 Vertically Infected Kenyan Children.

Authors:  Matilda Chelimo Saina; Xiuqiong Bi; Raphael Lihana; Raphael Lwembe; Azumi Ishizaki; Annie Panikulam; Tresa Palakudy; Rachel Musoke; Mary Owens; Elijah Maritim Songok; Hiroshi Ichimura
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.